As the interim medical co-director of the Stanford Cancer Center, it is my privilege to partner with my colleagues in advancing innovative research and high quality, coordinated, and compassionate care for our patients.
- Fellowship: Stanford University Hematology and Oncology Fellowship (2012) CA
- Residency: Stanford University Internal Medicine Residency (2010) CA
- Medical Education: UCLA David Geffen School Of Medicine Registrar (2007) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2013)
- Board Certification: American Board of Internal Medicine, Hematology (2013)
- Board Certification, Oncology (2013)
- Board Certification, Hematology (2013)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2010)
Late presentation of dyskeratosis congenita.
Shomali, W., & Brar, R. (2019). Late presentation of dyskeratosis congenita. British Journal of Haematology.
A Kindred with a ß-Globin Base Substitution [ß89(F5)Ser?Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt.
Shomali, W., Brar, R., Arekapudi, S. R., & Gotlib, J. R. (2019). A Kindred with a ß-Globin Base Substitution [ß89(F5)Ser?Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt. Hemoglobin, 1–4.
A Case of G6PC3 Congenital Neutropenia, Misdiagnosed As Evans Syndrome
Camacho, J. V., Brar, R., Chapman, C., Fernandez-Pol, S., Weinacht, K., & Gernez, Y. (2020). A Case of G6PC3 Congenital Neutropenia, Misdiagnosed As Evans Syndrome. JOURNAL OF CLINICAL IMMUNOLOGY, 40(SUPPL 1), S131–S132.
Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes.
Alobuia, W. M., Perrone, K., Iberri, D. J., Brar, R. S., Spain, D. A., & Forrester, J. D. (2020). Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes. Surgery Open Science, 2(4), 19–24.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia »
- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome »
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia »
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia »
- A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia »
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) »
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy »
- Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma »
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) »
- Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission »
- Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL »
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy »
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive »
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) »
- Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion »
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL »
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study »
- A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome »
- Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis »
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia »
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia »
- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia »
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia »
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma »
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas »
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia »
Hematologic Cancer Program ,,
Hematologic Cancer Program
Hematology Program ,,
View More »